Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ambrx to Start US Clinical Trials of HER2 Cancer Drug

publication date: Aug 17, 2016
Ambrx, a San Diego-China biopharma, will start US clinical trials of ARX78, an antibody drug conjugate targeting HER2. Earlier this year, Ambrx started an Australia-New Zealand trial of the candidate, and China tests are planned. Ambrx, which out-licensed China rights for ARX78 to Zhejiang Medicine in 2013, expects ARX788 will be more effective for more indications than Roche's Herceptin. In 2015 Ambrx was acquired by a consortium of China companies, including Fosun Pharma and WuXi AppTec plus China equity investors HOPU and Everbright. More details....

Stock Symbols: (SHA: 600216) (SX: ROG) (SHA: 600196; HK: 02196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital